Brain metastases, particularly in non-small cell lung cancer patients, are among the common causes of disease progression with brain metastasis frequency in ALK inhibitor naive patients ranging from about 25 to 40%, which is high in patients with history of chemotherapy [47, 48]. Here, ALK is linked to non-small cell lung carcinoma.